Slide 1: Modelling in immuno-oncology
Modelling in immuno-oncology Biotrinity, April 2020 Copyright © Physiomics Plc 2020 - www.physiomics.co.uk
Slide 2: Physiomics brings together a unique combination of capabilities…
Physiomics brings together a unique combination of capabilities… Knowledge of Understanding of Expertise in Experience in cancer biology pre-clinical and quantitative modelling and AI from industry and clinical data sourcing pharmacology techniques such as academia and curation machine learning Slid
Slide 3: …to answer key development questions for our clients
…to answer key development questions for our clients Recommend efficacy/ toxicity trade-offs ✓ Predict biologically effective dose in humans to support clinical translation ✓ Recommend combination partner agent for proprietary in-house asset ✓ Slide 3 Copyright © Physiomics Plc 2020 - www.physiomics
Slide 4: Physiomics is a consultancy focused on quantitative modelling in oncology
Physiomics is a consultancy focused on quantitative modelling in oncology PK/PD analysis Quantitative Systems Pharmacology • Data analysis and interpretation • Pathway models • PK/PD modelling (NCA, • PBPK PopPK) • Literature, bespoke or hybrid • In-vitro, in-vivo, clinical Virtual Tumour™ Personali
Slide 5: We've completed over 70 commercial and grant funded projects
We’ve completed over 70 commercial and grant funded projects Big pharma Merck, MSD, Lilly, Bayer and others Grants Innovate UK, EU-FP6 (TEMPO), Carbon Trust 70 projects completed Biotech/ Midcap Bicycle Therapeutics, CRUK Cellcentric, Convert Pharma, and others Academic Medicines Discovery Catapult,
Slide 6: Our Virtual Tumour™ platform has been extended to enable modelling of immuno-oncology combination treatment
Our Virtual Tumour™ platform has been extended to enable modelling of immuno-oncology combination treatment SINGLE “AGENT” REPRESENTING X CELLS • Various abstracted immune pathways are incorporated: • Stimulatory effect of anti-PD-(L)1 on Tumour T-cell activation levels, leading to Core Virtual Tumo
Slide 7: Predicting timing effects of RT and anti-PD-L1 combination
This enables us to predict and explain timing effects in terms of species modelled – for example, RT + anti-PD-L1 A -Total DNA Damage B - Immunogenic Cell Death C - Active T Cells D - Cell Death Due To T Cells E - Tumour Volume Decreasing T-cell induced cell death and tumour regression 0d Offset of
Slide 8: Why work with Physiomics?
Why work with Physiomics? • We help solve real development challenges • We supplement existing client resources to increase capacity and shorten timelines • Exclusively focused on cancer • Deep expertise • >70 big pharma, biotech and grant funded projects • Significant academic as well as industry e
Slide 9: Contact form – we'd love to hear from you!
Our website www.physiomics.co.uk includes examples of our work and a contact form – we’d love to hear from you! Slide 9 Copyright © Physiomics Plc 2020 - www.physiomics.co.uk